Presurgical Cytoreduction of Oral Cancer Using Intra-arterial Cisplatin and Limited Concomitant Radiation Therapy (Neo-RADPLAT)

Abstract

To determine the effectiveness of a cytoreduction strategy for oral cancer using a novel trimodal therapy.

Selective intraarterial chemoradiation therapy for oropharyngeal carcinoma with high-dose cisplatin

“…The locoregional control rate of the present study was the same as that reported by Robbins et al [13][14][15][18][19][20][21] The locoregional control rates for oropharyngeal carcinoma in tonsils were 48%-80% for stage III and 22%-37% for stage IV. In the base of the tongue, these rates were 68%-81% for stage III and 17%-50% for stage IV in the PDQ database.…”

“…Therefore, we believe that an adequate rate of simultaneous administration of sodium thiosulfate is important. We performed intraarterial infusions of cisplatin at a higher dose than that reported by Robbins et al, 19 but our regimen used fewer intraarterial infusions of the cisplatin. There were fewer cases of grade III, IV, or V toxicity in the present study than were reported by Robbins et al The incidence of signifi cant toxicity was relatively low, although that of nephritic toxicity was signifi cant in the present study.…”

Reporting standards for endovascular chemotherapy of head, neck and CNS tumors

“…The data are summarized in online supplementary tables 1A–C; data were separated by pathology (1A: head and neck, 1B: eye, 1C: brain). For head and neck carcinomas there were two class II publications24 25 and 20 class III publications 2 5 8 26–42. Study numbers ranged from 4 to 117 patients (see online supplementary table 1A).…”

Cerebral revascularization and carotid artery resection at the skull base for treatment of advanced head and neck malignancies

“…With high rates of morbidity and mortality, poor postresection survival rates, and improved survival with chemoradiotherapy, 30,31 the role of aggressive resection has been questioned. 19 In some series of skull base tumors treated with adjuvant therapies, overall survival rates at 2 and 3 years have been reported at 80% and 36%, respectively.…”